68Ga-JH04 PET/CT: Dosimetry and Biodistribution Studies

Launched by FIRST AFFILIATED HOSPITAL OF FUJIAN MEDICAL UNIVERSITY · May 27, 2024

Keywords

ClinConnect Summary

This clinical trial is studying a new imaging tool called 68Ga-JH04, which helps doctors see how certain cancers are behaving in the body. Specifically, it targets a protein called fibroblast activation protein (FAP) that is often found in various types of tumors. The main goals of this study are to check how safe 68Ga-JH04 is, how it spreads throughout the body, and how much radiation it gives off. This research is important because it could help improve the way cancers are diagnosed and treated.

If you or a loved one has a solid tumor and are between the ages of 65 and 74, you may be eligible to participate in this trial. However, pregnant or breastfeeding women and those with serious liver or kidney problems cannot join. Participants will receive the 68Ga-JH04 radiotracer and will be closely monitored to ensure their safety during the study. This trial is currently recruiting participants, and being part of it could contribute to advancing cancer treatment options.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Various solid tumors with available histopathological findings
• • Signed informed consent
• Exclusion Criteria:
• • pregnant or lactational women
• • who suffered from severe hepatic and renal insufficiency

Trial Officials